Clinical Trial Update: PROactive Evaluation of Function to Avoid CardioToxicity [Phase 2]

View source ↗

Summary

The Phase 2 PROactive trial evaluating strategies to prevent cardiotoxicity in cancer patients was terminated, and results were posted in 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Leukemia
• Lung Cancer
• Lymphoma
• Myeloma
• Sarcoma

Snippet

Sponsor: Washington University School of Medicine | Conditions: Cardiotoxicity, Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2025-07-29